 CHARLOTTESVILLE, VA ACCESSWIRE March 26, 2020 Adial Pharmaceuticals, Inc. ADILADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it received an Issue Notification for the issuance of a patent by the United States Patent and Trademark Office USPTO for the treatment of Opioid Use Disorder OUD with its lead drug candidate, AD04, in people that are positive for select genotypes identified using the Companys propriety companion genetic test. Including the patent term adjustment provided in the Issue Notification, the patent is expected to provide commercial exclusivity for AD04 until September 2031, plus potential Hatch-Waxman extensions. 